Dipeptidylpeptidase-4 Inhibitors (Gliptins)Focus on Drug-Drug Interactions

被引：0
作者：
André J. Scheen
机构：
[1] University of Liege,Division of Clinical Pharmacology and Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Sart Tilman
[2] CHU Sart Tilman (B35),Department of Medicine
来源：
Clinical Pharmacokinetics | 2010年 / 49卷
关键词：
Metformin; Digoxin; Simvastatin; Pioglitazone; Sulfonylurea;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Patients with type 2 diabetes mellitus (T2DM) are generally treated with many pharmacological compounds and are exposed to a high risk of drug-drug interactions. Indeed, blood glucose control usually requires acombination of various glucose-lowering agents, and the recommended global approachto reduce overall cardiovascular risk generally implies administration of several protective compounds, including HMG-CoA reductase inhibitors (statins), antihypertensive compounds and antiplatelet agents.
引用
收藏
页码：573 / 588
页数：15
相关论文
共 224 条
[1]  
Scheen A.J.(1998)Oral antidiabetic agents: a guide to selection Drugs 55 225-36
[2]  
Lefebvre P.J.(2009)Medical management of hyper-glycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes Dia-betologia 52 17-30
[3]  
Nathan D.M.(2005)Oral antidiabetic agents: current role in type 2 diabetes mellitus Drugs 65 385-411
[4]  
Buse J.B.(2006)The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 1696-705
[5]  
Davidson M.B.(2007)Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug Diab Obes Metab 9 153-65
[6]  
Krentz A.J.(2008)Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database Syst Rev 2 CD006739-98
[7]  
Bailey C.J.(2009)Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin: diabetes control and potential adverse events Best Pract Res Clin Endocrinol Metab 23 487-84
[8]  
Drucker D.J.(2010)Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus Pharmacotherapy 30 463-45
[9]  
Nauck M.A.(1995)Antihyperglycaemic agents: drug interactions of clinical importance Drug Saf 12 32-31
[10]  
Idris S.(2005)Drug interactions of clinical importance with antihyperglycaemic agents: an update Drug Saf 28 601-41
12345678910